《Commercial Times》
- 網頁服務 安克
- Jul 5, 2024
- 1 min read
Updated: Oct 29
AmCad and Swiss Hospital Reveal Promising New Tech for OSA Treatment Success
Expands OSA Application - Paper in Otolaryngology–Head and Neck Surgery
AmCad BioMed has extended the clinical use of its AmCAD-UO, ultrasound obstructive sleep apnea (OSA) assessment system, through a collaboration with Bern University Hospital. Newly published in a leading peer-reviewed medical journal "Otolaryngology–Head and Neck Surgery", the study shows AmCAD-UO's value in predicting suitable patients for hypoglossal nerve stimulation (HNS) therapy, an FDA-approved implant for OSA, by combining sleep-disordered breathing severity assessment with ultrasound-based tongue tissue analysis. The method achieved nearly 80% accuracy, helping identify patients unlikely to benefit from HNS and potentially serving as a noninvasive, rapid alternative or complement to drug-induced sleep endoscopy (DISE).
General Manager Yili Lee noted this marks the third international journal publication for AmCAD-UO, following collaborations with Stanford Sleep Medicine Center published in "Sleep Medicine" and "JAMA Otolaryngology". The findings support better treatment selection, advancing precision medicine and global market opportunities for AmCad BioMed.